DRUG REGULATORY AUTHORITY OF PAKISTAN
DIVISION OF QUALITY ASSURANCE & LABORATORY TESTING

MEDICAL PRODUCT ALERT

DRAP ALERT NO. Nº I/S/11-26-63

Dexatob Ear Drops (Adulterated) and Alergocit tablet (Substandard)

Date: 26th November, 2026

Target Audience:

- Field Offices of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public.

Alert Summary:

Drug Testing Laboratory (DTL) Punjab, Multan has declared the below-mentioned drug products as Adulterated and Substandard. Following are the details:

S#	Product Name	Batch	Manufacturer	Remarks
1.	**Dexatob Ear Drops** (Tobramycin…..3mg Dexamethasone as Sodium Phosphate……1mg)	AS-208	Sante (Private) Limited, A-97, S.I.T.E Super Highway, Karachi	Drugs Testing Laboratory (DTL) Punjab, Multan has declared the product as "Adulterated" on the basis of presence of Dexamethasone Base in the product.
2.	**Alergocit 5mg tablet** Levocetirizine Dihydrochloride 5mg	26D027	Global Pharmaceuticals Pakistan, plot No. 8, street No. S-8, RCCI Industrial Estate Rawat.	Drugs Testing Laboratory (DTL) Punjab, Multan has declared the product as "Substandard" on the basis of organic impurity testing.

Risk Statement:

1. The presence of identified unwanted chemical compound in Dexatob Ear Drops may adversely affect the quality, safety, and efficacy of the product and may pose a potential risk to public health.
2. Elevated levels of organic impurities may adversely affect the quality, safety, and efficacy of the product and could potentially expose patients to unintended chemical substances, consequently, may pose a potential risk to public health.

Action initiated: -

The Provincial Drug Control departments have been asked to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.

DRAP, Islamabad
+92 051 9255969
gsms@dra.gov.pk

Advice for Pharmacies/Medical stores: -

All pharmacists and chemist working at distributions and pharmacies should **immediately check** their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.

Advice for Consumers/general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

Drug Regulatory Authority of Pakistan
محفوظ، موثر اور معیاری اشیائے